Eleonora Lugarà

Scripta Therapeutics is an Oxford-based techbio company that takes a biology-first approach to discover disease-modifying drugs that modulate transcription factor activity and reprogram biology. We aim to discover and develop therapeutics for neurodegenerative disorders. We are following a unique strategy, based on the concept that transcription factors, the master controllers of gene expression, are core drivers of disease and act as detailed and dynamic maps of disease. Therapeutics that modulate these maps to restore the healthy cell state can be efficiently identified by a data-rich, lab-in-the-loop combination of experimental biology with cutting-edge AI and informatics.

Scripta Therapeutics is an Oxford-based techbio company that takes a biology-first approach to discover disease-modifying drugs that modulate transcription factor activity and reprogram biology. We aim to discover and develop therapeutics for neurodegenerative disorders. We are following a unique strategy, based on the concept that transcription factors, the master controllers of gene expression, are core drivers of disease and act as detailed and dynamic maps of disease. Therapeutics that modulate these maps to restore the healthy cell state can be efficiently identified by a data-rich, lab-in-the-loop combination of experimental biology with cutting-edge AI and informatics.

Oxford Science Enterprises (OSE) exists to transform Oxford’s cutting-edge scientific research into companies to tackle the world’s greatest challenges. We strive for global impact and strong investor returns. We’re an independent investment company and venture builder, powered by a unique partnership with the University of Oxford. We have unrivalled access to world-leading science, and a 60+ strong team embedded in Oxford’s innovation ecosystem. Our proven venture-building engine systematically creates 8-10 new companies each year – and this is set to double by 2030. We find. We fund. We build. In our first decade, we’ve created 50+ core companies, partnered with 300+ co-investors, and together invested more than £3bn. And we’re only just getting started – with a new wave of Oxford spinouts emerging and later-stage companies scaling fast. Based in the heart of Oxford, our mission is clear: turning world-class science into transformational companies with global impact and billion-pound potential.

Global Biotech Revolution (GBR) is a youth-led nonprofit which connects and develops future leaders to accelerate the growth and advancement of the global biotech ecosystem. The flagship event of GBR is the GapSummit, an annual student-run world-class biotechnology leadership summit with the core objectives of substantively discussing pressing challenges facing the bio-economy and catalysing innovation to solve these challenges. As the only intergenerational conference of its kind, the GapSummit competitively selects 100 Leaders of Tomorrow from around the world to attend, and recruits current leaders across the global biotech community to inspire the next generation. Keep your eyes open for the next selection round!

The NHS was launched in 1948.

UCL (University College London) is Londons leading multidisciplinary university, ranked 9th in the QS World University Rankings. Established in 1826 UCL opened up education in England for the first time to students of any race, class or religion and was also the first university to welcome female students on equal terms with men. Today UCL is made up of remarkable people: eminent professors and exceptional students. Academic excellence and conducting research that addresses real-world problems inform our ethos to this day. To see more photos of UCL you can visit our Flickr Gallery: www.flickr.com/photos/uclnews/sets/ To view videos of UCL and our work, you can subscribe to our YouTube Channel: http://www.youtube.com/user/UCLTV Looking for a job at UCL? Find out more about working with us and view the latest vacancies: https://www.ucl.ac.uk/jobs